Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
159(c) 159.83(c) 162.95(c) 162.62(c) 160.12(c) Last
1 201 729 1 176 974 1 675 412 1 145 693 1 405 802 Volume
+0.03% +0.52% +1.95% -0.20% -1.54% Change
More quotes
Financials (USD)
Sales 2020 7 040 M - -
Net income 2020 -175 M - -
Net Debt 2020 6 852 M - -
P/E ratio 2020 -183x
Yield 2020 0,61%
Sales 2021 8 099 M - -
Net income 2021 1 122 M - -
Net Debt 2021 5 399 M - -
P/E ratio 2021 30,4x
Yield 2021 0,63%
Capitalization 33 189 M 33 189 M -
EV / Sales 2020 5,69x
EV / Sales 2021 4,76x
Nbr of Employees 19 900
Free-Float 66,5%
More Financials
Company
Zimmer Biomet Holdings specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (59.4%): knees replacement (59.2% of net sales), hips replacement (40.8%) ; - surgical products and traumatology equipment (22.5%); - spinal implants (9.4%); - dental... 
More about the company
Notations Surperformance© of Zimmer Biomet Holdings
Trading Rating : Investor Rating :
More Ratings
All news about ZIMMER BIOMET HOLDINGS
01/11ZIMMER BIOMET : Announces Webcast and Conference Call of Fourth Quarter 2020 Fin..
AQ
01/08ZIMMER BIOMET : Announces Webcast and Conference Call of Fourth Quarter 2020 Fin..
PR
01/07ZIMMER BIOMET : UBS Adjusts Price Target on Zimmer Biomet Holdings to $182 From ..
MT
01/04ZIMMER BIOMET : Guggenheim Upgrades Zimmer Biomet Holdings to Buy From Neutral; ..
MT
01/04ZIMMER BIOMET : Evercore ISI Upgrades Zimmer Biomet Holdings to Outperform From ..
MT
2020Stocks End Lower After Push for Higher Stimulus Payments Stalls in Senate
MT
2020ZIMMER BIOMET : Argus Adjusts Zimmer Biomet Holdings PT to $170 From $160, Maint..
MT
2020ZIMMER BIOMET HOLDINGS : Ex-dividend day for
FA
2020UPDATE : Zimmer Biomet Picked as Top 2021 Healthcare Stock Pick by Needham; Pric..
MT
2020ZIMMER BIOMET : Picked as Top 2021 Healthcare Stock Pick by Needham; Price Targe..
MT
2020ZIMMER BIOMET : Needham Adjusts Price Target on Zimmer Biomet Holdings to $185 F..
MT
2020ZIMMER BIOMET : Morgan Stanley Adjusts Price Target for Zimmer Biomet Holdings t..
MT
2020CORRECTION : Goldman Sachs Downgrades Zimmer Biomet Holdings to Buy From Convict..
MT
2020ZIMMER BIOMET : Goldman Sachs Adjusts Price Target for Zimmer Biomet Holdings to..
MT
2020ZIMMER BIOMET : SVB Leerink Adjusts Zimmer Biomet Holdings' Price Target to $175..
MT
More news
News in other languages on ZIMMER BIOMET HOLDINGS
2020ZIMMER BIOMET HOLDINGS : Veröffentlichung des Quartalsergebnisses
2020ZIMMER BIOMET HOLDINGS : publication des résultats trimestriels
2020ZIMMER BIOMET HOLDINGS : Veröffentlichung des Halbjahresergebnisses
2020ZIMMER BIOMET HOLDINGS : publication des résultats semestriels
2020Medicrea n’échappe pas au destin américain des medtech françaises
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS
More recommendations
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 30
Average target price 167,21 $
Last Close Price 160,12 $
Spread / Highest target 20,5%
Spread / Average Target 4,43%
Spread / Lowest Target -33,8%
EPS Revisions
Managers and Directors
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS3.91%33 189
ABBOTT LABORATORIES1.65%190 701
MEDTRONIC PLC-0.28%157 229
BECTON, DICKINSON AND COMPANY4.60%76 127
HOYA CORPORATION-2.24%50 041
ALIGN TECHNOLOGY, INC.6.15%44 726